Medical and pediatric oncology最新文献_第9页

Letter to the editor: Eyelid leukemia as a relapse sign of B‐cell type acute lymphoblastic leukemia 致编辑的信:眼睑白血病是B细胞型急性淋巴细胞白血病的复发迹象

Medical and pediatric oncology Pub Date : 2001-04-01 DOI: 10.1002/MPO.1120

Y. Tabata, T. Yoshihara, S. Shirakami, Y. Kohda, S. Hibi, S. Imashuku

引用次数: 6

Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide. 通过竞争性RT-PCR检测神经母细胞瘤中生长抑素受体2型基因表达与患者生存和生长抑素受体铟-111-戊戊肽显像有关。

Medical and pediatric oncology Pub Date : 2001-01-01 DOI: 10.1002/1096-911X(20010101)36:1<224::AID-MPO1054>3.0.CO;2-#

C. Orlando, C. C. Raggi, L. Bagnoni, R. Sestini, V. Briganti, G. La Cava, G. Bernini, G. Tonini, M. Pazzagli, M. Serio, M. Maggi

{"title":"Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide.","authors":"C. Orlando, C. C. Raggi, L. Bagnoni, R. Sestini, V. Briganti, G. La Cava, G. Bernini, G. Tonini, M. Pazzagli, M. Serio, M. Maggi","doi":"10.1002/1096-911X(20010101)36:1<224::AID-MPO1054>3.0.CO;2-#","DOIUrl":"https://doi.org/10.1002/1096-911X(20010101)36:1<224::AID-MPO1054>3.0.CO;2-#","url":null,"abstract":"BACKGROUND We previously reported that human neuroblastoma cell lines and primary neuroblastoma tumors expressed a variable amount of mRNA for type 2 somatostatin (sst2) receptor gene. We also found that high level of sst2 expression were positively related to patient survival. PROCEDURE We studied retrospectively 49 primary neuroblastomas. To detect and measure sst2 mRNA expression we developed a quantitative RT-PCR based on competitive PCR. When possible the number of MYCN copies was also measured with competitive PCR. RESULTS;. We found that the lowest level of sst2 mRNA was detected in advanced stages of neuroblastomas (stage IV) when compared with the other stages (P< 0.005). Patients with high levels of sst2 expression (>7 x 10(7) molecules/microg RNA) had a cumulative survival better than those with low sst2 expression (P < 0.0005). This predictive independent value of sst2 (P= 0.005) is retained after stratification for N-myc amplification. Finally we verified that the ex vivo sst2 gene expression in tumor samples was positively related (P < 0.01) to the in vivo semiquantitative determination of sst2 protein, assessed by 111In-pentetreotide imaging. CONCLUSIONS Our data indicate that the measurement of sst2 mRNA measurement could represent a relevant tool in the prediction of neuroblastoma outcome, independently from MYCN amplification.","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"36 1 1","pages":"224-6"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81221658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 31

Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. 单克隆抗体治疗后双神经节脂苷GD2丢失在神经母细胞瘤中是罕见的。

Medical and pediatric oncology Pub Date : 2001-01-01 DOI: 10.1002/1096-911x(20010101)36:1<194::aid-mpo1046>3.3.co;2-2

K. Kramer, W. Gerald, B. Kushner, S. Larson, M. Hameed, N. Cheung

{"title":"Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.","authors":"K. Kramer, W. Gerald, B. Kushner, S. Larson, M. Hameed, N. Cheung","doi":"10.1002/1096-911x(20010101)36:1<194::aid-mpo1046>3.3.co;2-2","DOIUrl":"https://doi.org/10.1002/1096-911x(20010101)36:1<194::aid-mpo1046>3.3.co;2-2","url":null,"abstract":"BACKGROUND Gangliosicle GD2 is abundant on human neuroblastoma (NB). Monoclonal antibody 3F8 targeted to GD2 may have imaging and therapeutic potential. Antigen-negative clones can escape immune-mediated attack leading to clinical resistance or recurrence. PROCEDURE Among 95 evaluable patients treated intravenously with 3F8 (94 Stage 4, 1 Stage 3), 66 received nonradiolabeled 3F8, 11 received 131-iodine-labeled-3F8 (8-28 mCi/kg) with autologous bone marrow rescue, and 18 received both forms of treatment. Prior to treatment, 90 patients tested positive for GD2 reactivity by bone marrow immunofluorescence (n = 68), tumor immunohistochemistry (n = 20), or diagnostic radioimmunoscintigraphy (n = 2). RESULTS Of 62 patients who had refractory or recurrent neuroblastoma following 3F8 treatment, 61 (98%) tested positive for GD2 reactivity by bone marrow immunofluorescence (n = 51) or tumor immunohistochemistry (n = 10). The sole tumor that lost GD2 expression underwent phenotypic transformation into a pheochromocytoma-like tumor. CONCLUSIONS The persistence of GD2 expression in refractory or recurrent NB suggests that complete antigen loss is an uncommon event and cannot account for treatment failure.","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"14 1","pages":"194-6"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88321574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors. 多药耐药相关蛋白1 (MRP1)在神经母细胞瘤细胞系和原发肿瘤中的表达。

Medical and pediatric oncology Pub Date : 2000-12-01 DOI: 10.1002/1096-911x(20001201)35:6<619::aid-mpo28>3.0.co;2-h

H Goto, N Keshelava, K K Matthay, J N Lukens, R B Gerbing, D O Stram, R C Seeger, C P Reynolds

{"title":"Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors.","authors":"H Goto, N Keshelava, K K Matthay, J N Lukens, R B Gerbing, D O Stram, R C Seeger, C P Reynolds","doi":"10.1002/1096-911x(20001201)35:6<619::aid-mpo28>3.0.co;2-h","DOIUrl":"https://doi.org/10.1002/1096-911x(20001201)35:6<619::aid-mpo28>3.0.co;2-h","url":null,"abstract":"Background and procedure: MRP1 expression by neuroblastomas was evaluated by Northern blot analysis in 21 cell lines and 90 primary untreated tumors. Cytotoxicity assay in cell lines was performed for five anticancer drugs used in treating neuroblastoma.Results: MRP1 expression did not correlate with drug resistance or with MYCN RNA expression in cell lines. MRP1 expression was higher in drug-sensitive cell lines established after chemotherapy relative to cell lines at diagnosis, but highly drug-resistant cell lines showed low MRP1 expression. Positive expression of MRP1 RNA in primary tumors was associated with a poorer survival relative to MRP1-negative tumors. However, MRP1 expression levels did not correlate with age, stage, MYCN amplification, or MYCN expression, and higher MRP1 expression was not associated with a worse outcome.Conclusions: In neuroblastoma, positive MRP1 RNA expression at diagnosis has prognostic significance, but high drug resistance is conferred by mechanisms other than MRP1.","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"35 6","pages":"619-22"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/1096-911x(20001201)35:6<619::aid-mpo28>3.0.co;2-h","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21931226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

Rapid-sequence tandem transplant for children with high-risk neuroblastoma. 儿童高危神经母细胞瘤的快速序列串联移植。

Medical and pediatric oncology Pub Date : 2000-12-01 DOI: 10.1007/978-3-642-55774-3_33

S. Grupp, J. W. Stern, N. Bunin, D. Allmen, G. Pierson, C. Nancarrow, R. Adams, G. Griffin, L. Diller

引用次数: 39

Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma. 转移性复发和难治性神经母细胞瘤的合作方案(N-III-95)的结果。

Medical and pediatric oncology Pub Date : 2000-12-01 DOI: 10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u

V Castel, A Cañete, C Melero, T Acha, A Navajas, P García-Miguel, T Contra, J Molina, P Galarón, O Cruz

引用次数: 10

Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents. 芬维啶和CD437的不同性质导致与化疗试剂的协同反应。

Medical and pediatric oncology Pub Date : 2000-12-01 DOI: 10.1002/1096-911x(20001201)35:6<663::aid-mpo39>3.0.co;2-4

P E Lovat, M Ranalli, F Bernassola, M Tilby, A J Malcolm, A D Pearson, M Piacentini, G Melino, C P Redfern

{"title":"Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents.","authors":"P E Lovat, M Ranalli, F Bernassola, M Tilby, A J Malcolm, A D Pearson, M Piacentini, G Melino, C P Redfern","doi":"10.1002/1096-911x(20001201)35:6<663::aid-mpo39>3.0.co;2-4","DOIUrl":"https://doi.org/10.1002/1096-911x(20001201)35:6<663::aid-mpo39>3.0.co;2-4","url":null,"abstract":"The RARbeta/gamma-selective retinoids fenretinide and CD437 induce caspase-dependent apoptosis but generate free radicals independently of caspases. Apoptosis, but not free radical generation, induced by these retinoids is inhibited by RARbeta/gamma-specific antagonists. Both fenretinide and CD437 induce apoptosis synergistically with cisplatin, carboplatin, or etoposide. However, antioxidants inhibit this synergy to the level obtained with chemotherapeutic drugs alone, and this implies that free radical generation is important in the synergistic response. Since apoptosis induced by fenretinide or CD437 is mediated by apoptotic pathways involving RARs and/or mitochondria and differs from mechanisms of chemotherapy-induced apoptosis this may explain the strong synergistic response seen between these synthetic retinoids and chemotherapeutic drugs. These results suggest that fenretinide or CD437 may be useful adjuncts to neuroblastoma therapy.","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"35 6","pages":"663-8"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/1096-911x(20001201)35:6<663::aid-mpo39>3.0.co;2-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21931058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. TNP-470对人神经母细胞瘤异种移植模型肿瘤生长的抑制作用。

Medical and pediatric oncology Pub Date : 2000-12-01 DOI: 10.1002/1096-911x(20001201)35:6<673::aid-mpo41>3.0.co;2-o

S Shusterman, S A Grupp, J M Maris

{"title":"Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470.","authors":"S Shusterman, S A Grupp, J M Maris","doi":"10.1002/1096-911x(20001201)35:6<673::aid-mpo41>3.0.co;2-o","DOIUrl":"https://doi.org/10.1002/1096-911x(20001201)35:6<673::aid-mpo41>3.0.co;2-o","url":null,"abstract":"Unlabelled: Background and Procedure High-risk neuroblastoma disease features are correlated with tumor vascularity, suggesting that angiogenesis inhibitors may be a useful addition to current therapeutic strategies. We therefore examined the efficacy of TNP-470 (TAP Pharmaceuticals, Deerfield, IL) in human neuroblastoma xenograft models.Results: Tumor growth rate was markedly inhibited in mice receiving TNP-470 administered alone with a treatment to control ratio (T/C) at day 21 = 0.4 (P <.001). TNP-470 also significantly inhibited tumorigenicity when administered shortly after xenograft inoculation (T/C at day 30 = 0.1, P <.001) and when administered following cyclophosphamide (T/C at day 35 = 0.1, P <.001).Conclusions: These data show that TNP-470 is a potent inhibitor of human neuroblastoma growth both alone and when given with conventional chemotherapy, suggesting that it may be a useful adjunctive therapy for high-risk neuroblastoma patients.","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"35 6","pages":"673-6"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/1096-911x(20001201)35:6<673::aid-mpo41>3.0.co;2-o","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21931060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma. 从自体神经母细胞瘤免疫患者b细胞库中选择人抗肿瘤单链Fv抗体。

Medical and pediatric oncology Pub Date : 2000-12-01 DOI: 10.1002/1096-911x(20001201)35:6<692::aid-mpo45>3.0.co;2-7

C Rossig, J G Nuchtern, M K Brenner

{"title":"Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma.","authors":"C Rossig, J G Nuchtern, M K Brenner","doi":"10.1002/1096-911x(20001201)35:6<692::aid-mpo45>3.0.co;2-7","DOIUrl":"https://doi.org/10.1002/1096-911x(20001201)35:6<692::aid-mpo45>3.0.co;2-7","url":null,"abstract":"Background: We used phage display technology to clone human recombinant antitumor antibodies from the antibody repertoire of neuroblastoma patients immunized with cytokine-gene transduced tumor cells.Procedure: Lymphocytes obtained from neuroblastoma patients either at diagnosis or after immunization with an autologous interleukin-2 gene transduced tumor vaccine were used to construct two human single-chain Fv (scFV) phage libraries. Tumor-reactive phage were characterized using ELISA, flow cytometry, and sequencing analysis.Results: The initial screening after panning on neuroblastoma cells yielded a substantially higher proportion of selectivity tumor-binding phage clones derived from the immunized patients library (12.9%) than from the unvaccinated patients library (0.8%). The antibodies stained the cells from several additional pediatric malignancies, including Ewing sarcoma and rhabdomyosarcoma, in the absence of binding to any normal tissue cultures or epithelial tumor cell lines. The pattern of reactivity was different from that of antibodies recognizing other widely distributed neuroblastoma-associated antigens, suggesting recognition of a novel shared tumor antigen.Conclusion: The human recombinant scFV antibodies reported here appear to represent a tumor-specific B-cell response induced by autologous tumor immunization and are potentially useful targeting moieties for the treatment of selected childhood tumors.","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"35 6","pages":"692-5"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/1096-911x(20001201)35:6<692::aid-mpo45>3.0.co;2-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21931063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results. 以人群为基础的对照研究评估德国1岁时的神经母细胞瘤筛查:中期结果

Medical and pediatric oncology Pub Date : 2000-12-01 DOI: 10.1002/1096-911x(20001201)35:6<701::aid-mpo47>3.0.co;2-s

F H Schilling, F Berthold, R Erttmann, J Michaelis, C Spix, J Sander, K Schwarz, J Treuner

{"title":"Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results.","authors":"F H Schilling, F Berthold, R Erttmann, J Michaelis, C Spix, J Sander, K Schwarz, J Treuner","doi":"10.1002/1096-911x(20001201)35:6<701::aid-mpo47>3.0.co;2-s","DOIUrl":"https://doi.org/10.1002/1096-911x(20001201)35:6<701::aid-mpo47>3.0.co;2-s","url":null,"abstract":"Background: The German Neuroblastoma Screening Project is the first controlled and population-based screening study to evaluate the presumed benefit of neuroblastoma mass screening at 1 year of age (10-18 months).Procedure: Screening takes place in 6 of the 16 German states; children from the remainder serve as controls. The German Childhood Cancer Registry enables a mostly complete follow-up and detection of false-negative patients.Results: Up to December, 1999, 1,199,165 children were examined for urinary catecholamine metabolites and 124 cases of neuroblastoma were detected preclinically, giving a detection rate of 10.3/100,000. Within this cohort, 33 false-negative cases were found.Conclusions: The results of this screening program will be crucial for further implementation of neuroblastoma screening.","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"35 6","pages":"701-4"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/1096-911x(20001201)35:6<701::aid-mpo47>3.0.co;2-s","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21930402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11